- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04400071
Biology and Benefits of Music Play and Stories for Kids/Parents During ALL Treatment
March 10, 2024 updated by: Sheri Robb, Indiana University
Biologic Mechanisms and Dosing of Active Music Engagement in Children With Acute Lymphoblastic Leukemia and Parents
Music therapy has become a standard palliative care service in many pediatric and adult hospitals; however, a majority of music therapy research has focused on the use of music to improve psychosocial dimensions of health, without considering biological dimensions.
This study builds on prior work examining the psychosocial mechanisms of action underlying an Active Music Engagement (AME) intervention, designed to help manage emotional distress and improve positive health outcomes in young children with cancer and parents, by examining its effects on biomarkers of stress and immune function.
The purposes of this two group, randomized controlled trial are to examine biological mechanisms of effect and dose-response relationships of AME on child/parent stress during the consolidation phase of Acute Lymphoblastic Leukemia (ALL) treatment.
Specific aims are to: Aim 1. Establish whether AME lowers child and parent cortisol during ALL treatment.
Aim 2. Examine cortisol as a mediator of AME effects on child and parent outcomes during ALL treatment.
Aim 3 (exploratory).
Examine the dose-response relationship of AME on child and parent cortisol during ALL treatment.
Findings will provide a more holistic understanding about how active music interventions work to mitigate cancer-related stress and its potential to improve immune function, with direct implications for the evidence-based use of music to improve health.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Music therapy has become a standard palliative care service in many pediatric and adult hospitals.
However, a majority of music therapy research has focused on the use of music to improve psychosocial dimensions of health, without considering biological dimensions.
In addition, few studies have examined dose-response relationships.
Cancer treatment is an inherently stressful experience, and a significant number of young children and parents (caregivers) experience persistent, interrelated emotional distress and poor quality of life.
Many parents also experience traumatic stress symptoms because of their child's cancer diagnosis and treatment.
The investigators previously tested an Active Music Engagement (AME) intervention that uses active music play to diminish stressful attributes of cancer treatment to help manage emotional/traumatic distress experienced by young children (ages 3-8) and parents and improve quality of life.
A recent AME trial is examining psychosocial mechanisms of action responsible for change in child/parent outcomes.
The current study expands on this work by examining AME's effects on several biomarkers to provide a more holistic understanding about how active music interventions work to mitigate cancer-related stress and its potential to improve immune function.
The purposes of this two group, randomized controlled trial are to examine biological mechanisms of effect and dose-response relationships of AME on child/parent stress during the consolidation phase of Acute Lymphoblastic Leukemia (ALL) treatment.
Specific aims are to: 1) establish whether AME lowers child and parent cortisol, 2) examine cortisol as a mediator of AME effects on child and parent outcomes, and 3) examine the dose-response relationship of AME on child and parent cortisol.
Child/parent dyads (n=250) will be stratified (by age, site, ALL risk level) and randomized in blocks of four to AME or attention control.
Each group will receive one 45-minute session during weekly clinic visits for the duration of ALL consolidation (4 weeks standard risk; 8 weeks high risk).
Parents will complete measures at baseline and following the last study session.
Child and parent salivary cortisol samples will be taken pre and post-session for the first 4 AME or attention control sessions.
Child blood samples will be reserved from routine blood draws prior to sessions 1 and 4 (all participants) and session 8 (high risk participants).
Linear mixed models will be used to estimate AME's effect on child and parent cortisol.
Examining child and parent cortisol as mediators of AME effects on child and parent outcomes will be performed in an ANCOVA setting, fitting the appropriate mediation models using MPlus and then testing indirect effects using the percentile bootstrap approach to estimate the indirect effect.
Graphical plots and non-linear repeated measures models will be used to examine the dose-response relationship of AME on child and parent cortisol.
Study Type
Interventional
Enrollment (Estimated)
250
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sheri L Robb, PhD
- Phone Number: 317-274-3152
- Email: shrobb@iu.edu
Study Contact Backup
- Name: Claire J Kendrick, MM
- Phone Number: 317-278-0853
- Email: cjkendri@iu.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
Contact:
- Jenny Shoop, DNP
- Email: jshoop@luriechildrens.org
-
Principal Investigator:
- Jenny Shoop, DNP
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Riley Hospital for Children
-
Contact:
- Sheri L Robb, PhD
- Phone Number: 317-274-3152
- Email: shrobb@iu.edu
-
Contact:
- Claire J Kendrick, MM
- Phone Number: 317-278-0853
- Email: cjkendri@iu.edu
-
Principal Investigator:
- Sheri L Robb, PhD
-
Sub-Investigator:
- Susan M Perkins, PhD
-
Sub-Investigator:
- Timothy E Stump, PhD
-
Sub-Investigator:
- Seethal Jacob, MD
-
Sub-Investigator:
- Kristen A Russ, PhD
-
Sub-Investigator:
- Steven J Holochwost, PhD
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Recruiting
- Children's Mercy Hospital
-
Contact:
- Kristin Stegenga, PhD
- Email: kstegenga@cmh.edu
-
Principal Investigator:
- Kristin Stegenga, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 years to 8 years (Child)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Child is 3 - 8 years of age at time of enrollment
- Child has diagnosis of standard or high risk B- or T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LyLy)
- Child is currently receiving induction therapy
- One parent (>18 years of age) can be present for all sessions.
Exclusion Criteria:
- Child has Ph+ ALL,
- Child has Cushing disease,
- Child is taking steroid medication for asthma and/or has asthma that is not well controlled,
- The parent does not speak English, or
- The child has a significant cognitive impairment that might hinder participation (determination made in consultation with attending physician, oncologist, and parents).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active Music Engagement
See intervention description.
|
Weekly 45-minute sessions with a board-certified music therapist delivered during weekly clinic visits for the consolidation phase of ALL treatment.
Children with standard risk ALL will receive 4 sessions over 4 weeks.
Children with high risk ALL will receive 8 sessions over 8 weeks.
Sessions are delivered in a private setting during regularly scheduled clinic appointments.
During the first visit, parent and child will receive information on how they can use music play activities to help manage distress during treatment.
The music therapist will lead parent and child in a variety of music play activities.
Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD.
During subsequent visits the music therapist will lead parent and child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
|
Active Comparator: Audio Storybooks
See intervention description.
|
Weekly 45-minute sessions with a trained provider delivered during weekly clinic visits for the consolidation phase of ALL treatment.
Children with standard risk ALL will receive 4 sessions over 4 weeks.
Children with high risk ALL will receive 8 sessions over 8 weeks.
Sessions are delivered in a private setting during regularly scheduled clinic appointments.
Each session children/parents will choose and listen to one of three illustrated children's books with audio-recorded narration.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Child and Parent Stress (Salivary Cortisol)
Time Frame: Pre/Post-Sessions 1, 2, 3, and 4 (each session is 7 days apart; each session has a 45 min. duration).
|
We will measure salivary cortisol (a steroid hormone) as a biological indicator of stress.
Cortisol is one of the most frequently used biomarkers for stress and has been used in several cancer studies.
|
Pre/Post-Sessions 1, 2, 3, and 4 (each session is 7 days apart; each session has a 45 min. duration).
|
Change in Immunomodulatory Cytokines (children only) (blood)
Time Frame: Pre-Session Week 1 and Week 4 (all child participants); and Pre-Session Week 8 (only high risk child participants).
|
We will measure serum levels of IL-1β, IL-6, TNF-α, IFN-γ, IL-4, IL-10, and IL-13.
The activation of the HPA-axis has been reported to shift to promote the secretion of anti-inflammatory cytokines (IL-4, IL-10, IL-13) and decrease pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, IFN-γ) and thus modulate immune function.
|
Pre-Session Week 1 and Week 4 (all child participants); and Pre-Session Week 8 (only high risk child participants).
|
Change in Child Health Questionnaire-Mental Health Subscale (CHQ)
Time Frame: Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants)
|
Measures the frequency of both negative and positive states.
Items capture anxiety, depression, and positive affect.
We chose the parent-report version due to our targeted child age range of 3-8 years; parent-proxy and child self-report measures are scored differently, so we elected to use parent-proxy for all children.
The subscale includes 16 parent-report items on a 5-point Likert-scale, ranging from 1 (none of the time) to 5 (all of the time).
Scores range from 16-80 with higher scores indicating better mental health.
Across 25 subgroups, the median Cronbach alpha coefficient for the subscale was .76,
coefficients ranged from .67 to .86.
|
Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants)
|
Change in KINDLR Questionnaire for Measuring Health-Related Quality of Life in Children
Time Frame: Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants).
|
Measures global quality of life.
The KINDL is used widely and has been translated into 11 languages.
It was selected over other well-known measures for its positive health perspective, especially for younger children.
The KINDL consists of 24 parent-report items rated on a 5-point Likert-scale, ranging from 1 (never) to 5 (all the time).
There are 6 subscales: Physical well-being, Emotional Well-being, Self-Esteem, Family, Friends, and Everyday Functioning.
We will use 20 items in 5 subscales, omitting the Everyday Functioning subscale, because it is focused on school-related functioning and children may not be attending school.
Scores range from 20 - 100 with higher scores indicating better quality of life.
KINDL parent-report is a valid and reliable measure for children as young as age 3. The KINDL has satisfactory convergent and discriminant validity, and a Cronbach alpha of .89
for the total scale.
|
Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants).
|
Change in Profile of Mood States - Short Form (POMS-SF)
Time Frame: Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants).
|
Measures mood disturbance.
The scale is a self-report, 37-item instrument that yields scores on six subscales (tension-anxiety; depression-dejection; anger-hostility; vigor-activity; fatigue-inertia; confusion-bewilderment) and a total mood disturbance score.
Respondents are given 37 adjectives used to describe feelings during the last week and asked to respond to each item using a 5-point Likert scale (0 = not at all; 4 = extremely).
Higher scores equal greater mood disturbance.
Construct validity is widely supported.
The POMS-SF strongly correlates with the original 65-item POMS (r = 0.99) and is one of the most commonly used measures for parent emotional distress in pediatric cancer research.
|
Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants).
|
Change in Impact of Events Scale - Revised (IES-R)
Time Frame: Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants).
|
A 22-item measure that measures traumatic stress symptoms in response to a traumatic event that is specified in the instructions.
In our study, parents will respond to items in reference to their child's cancer treatment as the stressor.
The scale includes three subscales: intrusion, avoidance, and hyperarousal.
Parents respond to each item using a 5-point Likert scale (0 = not at all; 4 = extremely).
Higher scores indicate greater traumatic stress symptoms.
The IES-R has been used in studies of childhood cancer patients and their parents.
Cronbach's alpha for Intrusion, Avoidance, and Hyperarousal scales were .91,
.84,
and .90
respectively.
|
Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants).
|
Change in Index of Well-being
Time Frame: Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants)
|
A 9-item semantic differential scale describing present life using adjective extremes such as discouraging/hopeful. Higher scores mean greater well-being.
The scale has well established construct validity and a reported Cronbach alpha of .93 for the total scale.
|
Baseline; Post-Session Week 4 (standard risk participants); Post-Session Week 8 (high risk participants)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Sheri L Robb, PhD, Indiana University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Robb SL, Clair AA, Watanabe M, Monahan PO, Azzouz F, Stouffer JW, Ebberts A, Darsie E, Whitmer C, Walker J, Nelson K, Hanson-Abromeit D, Lane D, Hannan A. A non-randomized [corrected] controlled trial of the active music engagement (AME) intervention on children with cancer. Psychooncology. 2008 Jul;17(7):699-708. doi: 10.1002/pon.1301. Erratum In: Psychooncology. 2008 Sep;17(9):957.
- Robb SL, Haase JE, Perkins SM, Haut PR, Henley AK, Knafl KA, Tong Y. Pilot Randomized Trial of Active Music Engagement Intervention Parent Delivery for Young Children With Cancer. J Pediatr Psychol. 2017 Mar 1;42(2):208-219. doi: 10.1093/jpepsy/jsw050.
- Robb SL. The effect of therapeutic music interventions on the behavior of hospitalized children in isolation: developing a contextual support model of music therapy. J Music Ther. 2000 Summer;37(2):118-46. doi: 10.1093/jmt/37.2.118.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 7, 2020
Primary Completion (Estimated)
June 30, 2025
Study Completion (Estimated)
June 30, 2025
Study Registration Dates
First Submitted
May 15, 2020
First Submitted That Met QC Criteria
May 19, 2020
First Posted (Actual)
May 22, 2020
Study Record Updates
Last Update Posted (Actual)
March 13, 2024
Last Update Submitted That Met QC Criteria
March 10, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R01NR019190 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Lymphoblastic Leukemia, Pediatric
-
Emory UniversityTerminatedPediatric Acute Myeloblastic Leukemia, Relapsed | Pediatric Acute Lymphoblastic Leukemia, RelapsedUnited States
-
MedImmune LLCTerminatedB-Cell Pediatric ALLUnited States, Australia, France, Spain, Canada, Netherlands, United Kingdom, Italy
-
University of BirminghamAstraZeneca; Cancer Research UKTerminatedAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia RecurrentUnited Kingdom, Denmark, Netherlands
-
Beijing Boren HospitalRecruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic LeukemiaChina
-
University College, LondonNot yet recruitingAcute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia, Adult | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission
-
Tanja Andrea GruberRecruitingAcute Lymphoblastic Leukemia, Pediatric | Refractory Acute Lymphoblastic Leukemia | Relapsed Acute Lymphoblastic LeukemiaUnited States
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved RemissionUnited States
-
Children's Mercy Hospital Kansas CityCompletedRefractory Acute Myeloid Leukemia | Refractory Acute Lymphoblastic Leukemia | Relapsed Pediatric AML | Relapsed Pediatric ALLUnited States
-
Columbia UniversityAmerican Cancer Society, Inc.; Gabrielle's Angel FoundationActive, not recruitingAcute Lymphoblastic Leukemia, Pediatric | Obesity, PediatricUnited States
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI)RecruitingLeukemia | Acute Lymphoblastic Leukemia | Pediatric Acute Lymphoblastic LeukemiaUnited States
Clinical Trials on Active Music Engagement
-
Indiana UniversityM.D. Anderson Cancer Center; Children's Mercy Hospital Kansas City; Children's...Completed
-
MetroHealth Medical CenterThe Cleveland Music School Settlement; Kulas FoundationCompleted
-
Thomas Jefferson UniversityHeart and Diabetes Center North Rhine-Westphalia; Inova Fairfax Hospital; Resmed... and other collaboratorsTerminatedHeart Failure | Sleep Disorder; Breathing-RelatedUnited States, Germany
-
Oregon Health and Science UniversityNational Institute on Aging (NIA)CompletedCognitive Change | Mild Cognitive ImpairmentUnited States
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences InstituteCompletedAutonomic Nervous System Imbalance | Hypothalamic Pituitary Adrenal Axis SuppressionUnited States
-
Wayne State UniversityCompletedNeurological DisordersUnited States
-
University of AarhusDanish Cancer Society; TrygFonden, Denmark; Børnecancerfonden; Ronald McDonalds...Unknown
-
University of MalayaCompletedStroke | Dementia | Traumatic Brain InjuryMalaysia
-
Freedom Laser, Inc.NST Consultants, Inc.Completed
-
Hospices Civils de LyonRecruiting